Table 1:
Patient Characteristics According to Treatment Arm and Risk Group.
| Standard risk | High Risk | |||||
|---|---|---|---|---|---|---|
| Treatment arm | Auto-auto N (%) | Auto-allo N(%) | Total N(%) | Auto-auto N (%) | Auto-allo N (%) | Total N(%) |
| Number of patients | 436 | 189 | 625 | 48 | 37 | 85 |
| Sex (male) | 260 (60) | 111 (59) | 371 (59) | 27 (56) | 21 (57) | 48 (56) |
| Race | ||||||
| White | 335 (77) | 161 (85) | 496 (79) | 38 (79) | 33 (89) | 71 (84) |
| Black | 77 (18) | 18 (10) | 95 (15) | 8 (17) | 3 (8) | 11(13) |
| Other | 24 (6 | 10 (5) | 34 (6) | 2 (4) | 1 (3) | 3 (3) |
| Hispanic ethnicity | 18 (4) | 15 (8) | 33(5) | 3 (6) | 4 (11) | 7 (8) |
| Age | ||||||
| Median(range) | 55 (23-71) | 53 (29-68) | 55 (23-71) | 57 (32-71) | 51 (32-66) | 55 (32-71) |
| >=60 | 117 (27) | 28 (15) | 143 (23) | 14 (29) | 4(11) | 18 (21) |
| Stage at Diagnosis | ||||||
| Stage I/II | 436 (100) | 189 (100) | 625 (100) | 40(83) | 33 (89) | 73 (86) |
| Beta 2 Microglobulin > 4.0 | 0 | 0 | 0 | 42 (88) | 20 (54) | 62 (73) |
| Deletion 13 Present | 1 (<1) | 4 (2) | 5 (<1) | 5 (10) | 12 (32) | 17 (20) |
| Karnofsky score | ||||||
| >=90 | 262 (60) | 121 (64) | 383 (61) | 25 (52) | 24 (65) | 49 (58) |
| <90 | 102 (23) | 44 (23) | 146 (23) | 17 (35) | 9 (24) | 26 (31) |
| Missing | 72 (17) | 24 (13) | 96 (15) | 6 (13) | 4 (11) | 10 (12) |
| Type of Induction Therapy | ||||||
| VAD based | 113 (26) | 36 (19) | 149 (24) | 15 (31) | 8 (22) | 23 (27) |
| Thalidomide based | 258 (59) | 114 (60) | 372 (60) | 19 (40) | 21 (57) | 40 (47) |
| Bortezomib based | 39 (9) | 26 (14) | 65 (10) | 10 (21) | 7 (19) | 17 (20) |
| Other | 15 (3) | 6 (3) | 21 (3) | 2 (4) | 0 | 2 (2) |
| Missing | 11 (3) | 7 (4) | 18 (3) | 2 (4) | 1 (3) | 3 (4) |
| Disease Status at Registration | ||||||
| CR/nCR | 106 (24) | 46 (25) | 152 (24) | 2 (4) | 5 (13) | 7 (8) |
| VGPR | 79 (18) | 32 (17) | 111 (18) | 1 (2) | 7 (19) | 8 (9) |
| PR | 158 (36) | 76 (40) | 234 (37) | 21 (44) | 14 (38) | 35 (41) |
| MR/SD | 52 (12) | 23 (12) | 75 (12) | 16 (34) | 7 (19) | 23 (26) |
| Unknown | 41 (9) | 12 (6) | 53 (8) | 8 (17) | 4 (11) | 12 (14) |
| Median Time Dx to HCT #1 | 7 (<1-232) | 7 (<1-34) | 7 (<1-232) | 7 (5-22) | 7 (3-38) | 7 (3-38) |
| Actual Treatment Given | ||||||
| Tandem Auto + Thal/Dex | 179 (41) | 0 | 179 (29) | 16 (33) | 0 | 16 (19) |
| Tandem Auto + No Maintenance | 187 (43) | 0 | 187 (30) | 15 (31) | 0 | 15 (18) |
| Auto/Allo | 0 | 156 (83) | 156 (25) | 0 | 29 (78) | 29 (34) |
| Single Auto | 69 (16) | 33 (17) | 102 (16) | 17 (35) | 8 (22) | 25 (29) |
| No transplant | 1 (<1) | 0 | 1 (<1) | 0 | 0 | 0 |
| Median follow-up of survivors (range), months | 124 (2-161) | 124 (8-153) | 124 (2-161) | 134 (5-168) | 148 (88-152) | 146 (5-168) |